Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were $124.2 million, as compared to $152.8 million as of December 31, 2024. The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its current operational plans through 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics
- Cathie Wood Snags Robinhood Stock (HOOD) and GitLab (GTLB) as Markets Slide
- Repare Therapeutics Announces Leadership Changes in 2025
- Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds